The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion recommending upadacitinib for treating adult and adolescent patients with non-segmental vitiligo, a chronic autoimmune skin disease. This recommendation is based on Phase 3 clinical trials showing significant skin repigmentation improvements after 48 weeks of treatment. If approved by the European Commission, upadacitinib would become the first systemic medication for this condition, addressing a major unmet need. The drug is already approved for several other immune-related diseases but not yet for vitiligo in the EU.
The European Medicines Agency's CHMP has given a positive opinion recommending approval of AbbVie's upadacitinib for treating severe alopecia areata in adults and adolescents. This recommendation follows Phase 3 trial data showing significant hair re...
The JPMorgan Equity Premium Income ETF (JEPI) pays monthly distributions currently yielding about 8.3%, but the payment amount fluctuates due to its strategy of selling out-of-the-money call options, which generate premiums that depend on market vola...
The FDA has approved SKYRIZI (risankizumab-rzaa) for treating children aged six and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis. This approval includes a new 55 mg pre-filled syringe designed for weight-based dosing i...
Shares of AbbVie, Eli Lilly, and Johnson & Johnson are reaching all-time highs, reflecting renewed investor interest in the biopharmaceutical sector. AbbVie's recent announcement to acquire Apogee Therapeutics boosted its stock by 12%. Analysts attri...
Vanguard High Dividend Yield Index Fund ETF (VYM) provides income through dividends from over 500 U.S. stocks, focusing on large, profitable companies like Broadcom and JPMorgan Chase. With a very low expense ratio of 0.04%, nearly all dividends are ...
